Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 1 | Biomarker Research

Fig. 1

From: PAQR5 drives the malignant progression and shapes the immunosuppressive microenvironment of hepatocellular carcinoma by activating the NF-κB signaling

Fig. 1

Aberrant over-expression and poor prognosis of PAQR5 in HCC. A, B The PAQR5 mRNA expression of paired HCC samples and unpaired HCC samples in TCGA-LIHC cohort. C, D The validation of PAQR5 mRNA expression of HCC samples in GSE39791 cohort and TCGA-GTEx cohort. E, F, G Survival differences between high and low PAQR5 expression groups. Overall survival (OS), progression-free interval (PFI), and disease-specific survival (DSS). H Association between HCC Stage and PAQR5 expression. I PAQR5 as independent prognostic factors for HCC patients in Cox regression analysis. HR, hazard ratio. *p < 0.05; **p < 0.01; ***p < 0.001

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us